13 imidlertid udvalgets standpunkt, dvs. at indikationen bør indskrænkes til udvalgte patienter med lokalt avanceret prostatacancer og høj risiko for progression af sygdommen.
However, these data do support the Committee’ s position that the indication should be restricted to selected patients with locally advanced prostate cancer at high risk of disease progression.